Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) Operating Expenses (2020 - 2025)

Historic Operating Expenses for Rani Therapeutics Holdings (RANI) over the last 6 years, with Q3 2025 value amounting to $7.3 million.

  • Rani Therapeutics Holdings' Operating Expenses fell 3849.48% to $7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.9 million, marking a year-over-year decrease of 1131.08%. This contributed to the annual value of $54.3 million for FY2024, which is 1778.7% down from last year.
  • According to the latest figures from Q3 2025, Rani Therapeutics Holdings' Operating Expenses is $7.3 million, which was down 3849.48% from $10.5 million recorded in Q2 2025.
  • In the past 5 years, Rani Therapeutics Holdings' Operating Expenses registered a high of $27.8 million during Q3 2021, and its lowest value of $6.0 million during Q1 2021.
  • In the last 5 years, Rani Therapeutics Holdings' Operating Expenses had a median value of $13.8 million in 2022 and averaged $14.1 million.
  • In the last 5 years, Rani Therapeutics Holdings' Operating Expenses soared by 84654.17% in 2021 and then crashed by 4117.56% in 2022.
  • Rani Therapeutics Holdings' Operating Expenses (Quarter) stood at $13.4 million in 2021, then surged by 30.83% to $17.5 million in 2022, then dropped by 23.16% to $13.4 million in 2023, then rose by 19.0% to $16.0 million in 2024, then plummeted by 54.6% to $7.3 million in 2025.
  • Its Operating Expenses was $7.3 million in Q3 2025, compared to $10.5 million in Q2 2025 and $12.2 million in Q1 2025.